Incidence of Huntington disease in a northeastern Spanish region: A 13-year retrospective study at tertiary care centre

Bailo, P; Lahoz, Raquel; Marín, Juan Pelegrín Sánchez; Álvarez, Silvia Izquierdo

doi:10.21203/rs.3.rs-31294/v2

Cited by 1 publication

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Incidence A total of 18 studies examined the incidence of HD, with geographic representation across 12 countries (Canada, 12 Cyprus, 10 England, 9,22,23 Iceland, 24 Israel, 25 Italy, [26][27][28] Germany, 29 Greece, 30 South Korea, 31 Spain, 32,33 Sweden, 34 and the United States 35,36 ) (see Table S1 for study details).…”

Section: Meta-analysis Of Studies From 2011 To 2022mentioning

confidence: 99%

Prevalence and Incidence of Huntington's Disease: An Updated Systematic Review and Meta‐Analysis

et al. 2022

View full text Add to dashboard Cite

The incidence and prevalence of Huntington's disease (HD) based on a systematic review and meta‐analysis of 20 studies published from 1985 to 2010 was estimated at 0.38 per 100,000 person‐years (95% confidence interval [CI], 0.16–0.94) and 2.71 per 100,000 persons (95% CI, 1.55–4.72), respectively. Since 2010, there have been many new epidemiological studies of HD. We sought to update the global estimates of HD incidence and prevalence using data published up to February 2022 and perform additional analyses based on study continent. Medline and Embase were searched for epidemiological studies of HD published between 2010 and 2022. Risk of bias was assessed using a quality assessment tool. Estimated pooled prevalence or incidence was calculated using a random‐effects meta‐analysis. A total of 33 studies published between 2010 and 2022 were included. Pooled incidence was 0.48 cases per 100,000 person‐years (95% CI, 0.33–0.63). Subgroup analysis by continent demonstrated a significantly higher incidence of HD in Europe and North America than in Asia. Pooled prevalence was 4.88 per 100,000 (95% CI, 3.38–7.06). Subanalyses by continent demonstrated that the prevalence of HD was significantly higher in Europe and North America than in Africa. The minor increase in prevalence (more so than incidence) demonstrated in this updated review could relate to the enhanced availability of molecular testing, earlier diagnosis, increased life expectancy, and de novo mutations. Limitations include variable case ascertainment methods and lacking case validation data. © 2022 Her Majesty the Queen in Right of Canada. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. Reproduced with the permission of the Minister of Public Health Agency of Canada.

show abstract